Lambert Potin

Our oncology pipeline is growing! 🎉 We’re proud to announce that Debiopharm has obtained global rights from @novonordisk for the development of their ubiquitin-specific protease (USP1) inhibitor. Find out more about our new DDR inhibition compound . 👇 debiopharm.com/drug-developme…

Looking forward to being back in person at #BIO2022 in San Diego in June! Meet us at our booth 2219 to discuss #biopharmaceuticalresearch, #innovation and #partnering opportunities in #oncology and #bacterialinfections. Get in touch with our team via the event partnering system!

We're thrilled to collaborate with Neochromosome to accelerate next-generation cell therapy development. prn.to/31UI3wQ

D-Day for #BIOEuropeSpring Digital! Would you like to know more about Debiopharm or would you like to discuss #partnering opportunities in #oncology or #bacterialinfections? Visit our digital space and get in touch! ➡️ debiopharm.com/booth/bio-euro… #drugdevelopment

[NEWS] Debiopharm grants worldwide exclusive licensing to @MerckHealthcare for the development and commercialization of #xevinapant, currently in Phase III research for the treatment of #headandneckcancer ➡️ bit.ly/3bN1U22 #oncology | #healthcare |#drugdevelopment

Directement depuis le Lac Michigan 🌊 et Chicago, Léa Maillat (SV'13), présidente de l'antenne EPFL Alumni US Midwest, souhaite la bienvenue aux nouveaux diplômé-es. Son conseil: pensez aux alumni et n'hésitez pas à bénéficier de leur expérience. On se réjouit de vous accueillir!

First patient dosed for our phaseIII #TrilynX trial with #xevinapant in the treatment of #headandneckcancer. The study is being launched worldwide in over 200 sites. To have more information, please visit: bit.ly/33kME9v bit.ly/34ikDib

#ESMO20 Late Breaking Abstract presentation with #xevinapant in #headandneckcancer along with posters for two of our #oncology compounds that represent a few of the innovative ways that we're taking a stand against #cancer: bit.ly/32D1PKP